NCT01500863View on ClinicalTrials.gov

Endometrial Receptivity After GnRH Agonist Triggering

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Conditions
Ovarian Hyperstimulation Syndrome
Interventions
DRUG

hCG

single shot of 6500 IU hCG s.c. at the time of triggering

DRUG

triptorelin

single shot of 0.2mg triptorelin s.c. at the time of triggering

DRUG

Triptorelin, estradiol valerate, micronized vaginal progesterone

4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

DRUG

triptorelin, hCG

single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

DRUG

triptorelin, hCG

Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

DRUG

triptorelin, recombinant LH

300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

Trial Locations (1)

28035

Instituto Valenciano de Infertilidad, Madrid

All Listed Sponsors
lead

IVI Madrid

OTHER

NCT01500863 - Endometrial Receptivity After GnRH Agonist Triggering | Biotech Hunter | Biotech Hunter